MedTrace Logo

Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

NCT05476354 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 271

Last updated 2023-08-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate efficacy and safety of Irbesartan and Amlodipine combined therapy in patients with essential hypertension inadequately controlled on Irbesartan monotherapy

Conditions

  • Essential Hypertension

Interventions

DRUG

Irbesartan/Amlodipine low

Irbesartan/Amlodipine low once daily for 8 weeks

DRUG

Irbesartan/Amlodipine high

Irbesartan/Amlodipine high once daily for 8 weeks

DRUG

Irbesartan

Irbesartan once daily for 8 weeks

Sponsors & Collaborators

  • Handok Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-05
Primary Completion
2023-04-03
Completion
2023-06-13

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05476354 on ClinicalTrials.gov